We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $9.44B
1-Year Est. Return 157.3%
This Fund
S&P 500
This Quarter Est. Return
+42.01%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$6.4B
AUM Growth
+$1.32B
Cap. Flow
-$45.9M
Cap. Flow %
-0.72%
Top 10 Hldgs %
60.92%
Holding
71
New
5
Increased
8
Reduced
9
Closed
9

Top Buys

Rank Stock Value
1
IMGN
Immunogen Inc
IMGN
+$208M
2
GPCR icon
Structure Therapeutics
GPCR
+$27.9M
3
MGNX icon
MacroGenics
MGNX
+$25.7M
4
URGN icon
UroGen Pharma
URGN
+$20.8M
5
HARP
Harpoon Therapeutics, Inc. Common Stock
HARP
+$11.8M

Top Sells

Rank Stock Value
1
COGT icon
Cogent Biosciences
COGT
+$62.6M
2
ASND icon
Ascendis Pharma A/S
ASND
+$61M
3
CVAC
CureVac
CVAC
+$42.6M
4
SLNO
Soleno Therapeutics
SLNO
+$36.6M
5
VRDN icon
Viridian Therapeutics
VRDN
+$30.8M

Sector Composition

Rank Sector Weight
1 Healthcare 99.98%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASND icon
1
Ascendis Pharma A/S
ASND
$16.5B
$1.27B 19.88%
10,107,400
-612,155
-6% -$61M
IMGN
2
DELISTED
Immunogen Inc
IMGN
$704M 11%
23,750,601
+10,428,313
+78% +$208M
PCVX icon
3
Vaxcyte
PCVX
$7.64B
$496M 7.74%
7,891,254
– –
LEGN icon
4
Legend Biotech
LEGN
$3.66B
$377M 5.89%
6,264,707
– –
RYTM icon
5
Rhythm Pharmaceuticals
RYTM
$7.3B
$245M 3.83%
5,330,412
-345,655
-6% -$10.9M
JBIO
6
Jade Biosciences
JBIO
$1.18B
$187M 2.92%
236,114
– –
INBX
7
DELISTED
Inhibrx, Inc. Common Stock
INBX
$180M 2.8%
4,724,207
– –
CBAY
8
DELISTED
Cymabay Therapeutics
CBAY
$164M 2.56%
6,940,000
– –
BIIB icon
9
Biogen
BIIB
$30.9B
$138M 2.15%
532,892
– –
RXST icon
10
RxSight
RXST
$253M
$137M 2.14%
3,404,285
+351,489
+12% +$10.3M
ETNB
11
DELISTED
89bio
ETNB
$128M 1.99%
11,416,948
– –
VRNA
12
DELISTED
Verona Pharma
VRNA
$126M 1.96%
6,317,990
– –
DAWN
13
DELISTED
Day One Biopharmaceuticals
DAWN
$114M 1.78%
7,809,852
– –
ANTX icon
14
AN2 Therapeutics
ANTX
$181M
$114M 1.78%
5,551,295
– –
TYRA icon
15
Tyra Biosciences
TYRA
$1.85B
$100M 1.57%
7,236,454
– –
JANX icon
16
Janux Therapeutics
JANX
$910M
$98.3M 1.54%
9,165,652
– –
GERN icon
17
Geron
GERN
$911M
$97.5M 1.52%
46,202,425
– –
ICVX
18
DELISTED
Icosavax, Inc. Common Stock
ICVX
$94M 1.47%
5,963,565
– –
ALPN
19
DELISTED
Alpine Immune Sciences Inc
ALPN
$93.6M 1.46%
4,909,763
+218,585
+5% +$3.04M
WVE icon
20
Wave Life Sciences
WVE
$1.12B
$91.9M 1.44%
18,202,009
+1,000,000
+6% +$5.34M
NAMS icon
21
NewAmsterdam Pharma
NAMS
$3.27B
$87.8M 1.37%
7,864,000
-1,136,000
-13% -$10.4M
FDMT icon
22
4D Molecular Therapeutics
FDMT
$502M
$84.3M 1.32%
4,163,211
– –
EVH icon
23
Evolent Health
EVH
$370M
$84.2M 1.32%
2,549,132
-187,548
-7% -$5.31M
AXSM icon
24
Axsome Therapeutics
AXSM
$11.7B
$79.6M 1.24%
1,000,000
– –
FULC icon
25
Fulcrum Therapeutics
FULC
$240M
$78.4M 1.22%
11,609,704
– –
1
2 3

Similar funds

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
SCS Capital Management Boston, Massachusetts $9.44B AUM 18.1% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
AC
Allstate Corporation Northbrook, Illinois $9.35B AUM 16.13% 1-Year Est. Return
PVI
Partners Value Investments Hamilton, Bermuda $9.34B AUM 12.2% 1-Year Est. Return
WPL
WINDACRE PARTNERSHIP LLC Houston, Texas $9.34B AUM 17.41% 1-Year Est. Return
BAMF
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $9.55B AUM 31.94% 1-Year Est. Return

RA Capital Management's Q4 2023 Portfolio in Review

As of Q4 2023, RA Capital Management held 71 positions worth $6.4B, up 26% from $5.08B the previous quarter. Its ten largest holdings account for 61% of the portfolio.

RA Capital Management's Q4 2023 filing shows 5 new, 8 increased, 9 reduced and 9 closed positions. Its largest new stake was Structure Therapeutics: 486,832 shares worth $19.8M. The largest sale was Cogent Biosciences, an estimated $62.6M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier.

  • RA Capital Management's largest Q4 2023 buy was Structure Therapeutics: 486,832 shares worth $19.8M.
  • RA Capital Management added most to Immunogen Inc in Q4 2023, an estimated $208M increase.
  • RA Capital Management's biggest Q4 2023 reduction was Ascendis Pharma A/S, cutting an estimated $61M.
  • RA Capital Management fully exited Cogent Biosciences in Q4 2023, selling an estimated $62.6M.
  • RA Capital Management's ten largest holdings make up 61% of its $6.4B portfolio in Q4 2023.
  • RA Capital Management opened 5 new positions and closed 9 in Q4 2023.
  • RA Capital Management's portfolio value rose 26% quarter-over-quarter to $6.4B.

Based on RA Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.